Oral antibiotics for neonatal infections: a systematic review and meta-analysis by Keij, F.M. et al.
Oral antibiotics for neonatal infections: a systematic review
and meta-analysis
Fleur M. Keij1,2*, Rene´ F. Kornelisse1, Nico G. Hartwig2, Irwin K. M. Reiss1, Karel Allegaert1,3 and
Gerdien A. Tramper-Stranders1,2
1Department of Pediatrics, Division of Neonatology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands;
2Department of Pediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands; 3Department of Development
and Regeneration, KU Leuven, Leuven, Belgium
*Corresponding author. Department of Pediatrics, Division of Neonatology, Erasmus MC-Sophia Children’s Hospital, dr. Molewaterplein,
40, 3015 CN Rotterdam, The Netherlands.
E-mail: f.keij@erasmusmc.nl
Received 10 March 2019; returned 18 April 2019; revised 21 May 2019; accepted 21 May 2019
Background: Worldwide many neonates suffer from bacterial infections. Adequate treatment is important but
is associated with prolonged hospitalization for intravenous administration. In older children, oral switch therapy
has been proven effective and safe for several indications and is now standard care.
Objectives: To evaluate the currently available evidence on pharmacokinetics, safety and efficacy of oral antibi-
otics and oral switch therapy in neonates (0–28 days old).
Methods: We performed systematic searches in Medline, Embase.com, Cochrane, Google Scholar and Web of
Science. Studies were eligible if they described the use of oral antibiotics in neonates (0–28 days old), including
antibiotic switch studies and pharmacological studies.
Results: Thirty-one studies met the inclusion criteria. Compared with parenteral administration, oral antibiotics
generally reach their maximum concentration later and have a lower bioavailability, but in the majority of cases
adequate serum levels for bacterial killing are reached. Furthermore, studies on efficacy of oral antibiotics
showed equal relapse rates (OR 0.95; 95% CI 0.79–1.16; I2 0%) or mortality (OR 1.11; 95% CI 0.72–1.72; I2 0%).
Moreover, a reduction in hospital stay was observed.
Conclusions: Oral antibiotics administered to neonates are absorbed and result in adequate serum levels,
judged by MICs of relevant pathogens, over time. Efficacy studies are promising but robust evidence is lacking,
most importantly because in many cases clinical efficacy and safety are not properly addressed. Early oral anti-
biotic switch therapy in neonates could be beneficial for both families and healthcare systems. There is a need
for additional well-designed trials in different settings.
Introduction
Infections remain a main cause of morbidity and mortality among
newborns.1 Early-onset sepsis, defined as a proven bacterial infec-
tion in the first 72 h of life, has an overall incidence of1/1000 live
births, with a higher incidence in premature and/or very-low-birth-
weight infants.2 Forty-five percent of all childhood mortality under
5 years occurs in the neonatal period, of which 22% is due to neo-
natal infections, including pneumonia.3
Early diagnosis remains challenging due to non-specificity of
both clinical symptoms and laboratory findings.4 When bacterial
infection is probable or proven, parenteral antibiotics are usually
prescribed for at least 7 days.5 Occasionally, when intravenous (iv)
access problems occur, or when hospital referral is not possible, as
in low-and-middle-income countries (LMICs), newborns are
treated with oral antibiotics. In high-income countries (HICs), the
full course is generally completed iv.
Intravenous therapy and thus prolonged hospitalization inter-
feres with parent–child bonding and is associated with other
hospital-related risks and substantial costs.6,7 In older children,
oral switch therapy, defined as a switch to oral antibiotics within a
treatment course once the patient is clinically well, has been pro-
ven to be effective and safe for a variety of indications and is now
part of standard practice.8
The adequacy of antibiotic treatment depends on its specific
pharmacological mode of action. Efficacy of penicillins and cepha-
losporins, both commonly used drugs in neonatology, depends on
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T.MIC. For vancomycin, efficacy depends on AUC/MIC and for
aminoglycosides it depends on Cmax. The MIC is pathogen specific
and cut-off values vary by antibiotic.9,10
To our knowledge, no systematic review evaluating the use of
oral antibiotics in neonates has been performed. Together with the
uncertainties regarding oral absorption in the first weeks of life, the
lack of evidence may be a possible reason why oral switch therapy
is not yet standard care in neonates. The aim of this systematic re-
view is therefore to evaluate the currently available evidence on
safety and efficacy of iv-to-oral switch therapy in neonates, and
to evaluate whether, following oral antibiotic administration,
adequate serum concentrations are attainable in neonates
(0–28 days).
Methods
Search strategy and study selection
We performed a systematic review in accordance with the Preferred
Reported Items for Systematic Reviews and Meta-analysis (PRISMA),11
searching Medline, Embase.com, Cochrane Central, Google Scholar and
Web of Science on 22 February 2019. The PRISMA statement and full search
strategies can be found in the Supplementary data (available at JAC
Online). Titles and abstracts were screened and the full text of potential
articles was reviewed independently by two reviewers (F. M. K. and G. A. T.-
S.). Disagreements were resolved by discussion or through consultation
with a third investigator (R. F. K.). Congress abstracts, reference lists and
reviews were screened for additional studies. Eligible studies were limited
to those performed in humans. Since we expected the amount of evidence
to be small, we did not apply any restriction regarding year of publication or
language. We included randomized controlled trials (RCTs), intervention
studies and retrospective studies describing the use of oral antibiotics
including oral switch therapy and pharmacological studies in newborns 0–
28 days of age.
The protocol was registered in PROSPERO (protocol number
CRD42017070854).
Data extraction
Three authors (F. M. K., G. A. T.-S. and K. A.) independently extracted the
data following a predefined extraction form (see Supplementary data). We
did not contact authors for additional information.
Quality assessment
Quality assessment was performed independently by two authors (F. M. K.
and either K. A. or G. A. T.-S.) using the Cochrane Risk of Bias Tool for RCTs12
and the Newcastle–Ottawa Quality Assessment Scale (NOS) for non-
randomized trials.13 Since a tool for quality assessment of pharmacological
papers is currently lacking, we used the ClinPK statement, a descriptive tool
without a grading system, to assess quality of pharmacokinetics papers
(Table S2).14
Data analysis
When possible, data were pooled to assess efficacy of oral treatment. We
calculated pooled ORs with 95% CI using Review Manager V5.3.
Heterogeneity was assessed using Q statistics and I2 values and inter-
preted following the thresholds of the Cochrane Handbook for Systematic
Reviews of Interventions.15,16 A fixed-effects model was applied when het-
erogeneity was low (I2 ,40%), otherwise a random-effects model was
used. We performed a sensitivity analysis based on indication for antibiotic
treatment. In addition, a subgroup analysis was performed with respect to
the clinical indication and antibiotic regimen.
Results
From a total of 4559 studies, we reviewed the full text of 102 po-
tential articles. Figure 1 shows the selection process. Additionally,
five articles were selected through screening of reference lists,
leading to 31 selected publications for this review. The characteris-
tics of included studies are described in Table 1.
Quality assessment
Risk of bias in seven out of nine RCTs was low; in the remaining two
it was unclear (Figure S1).28,30 In all studies, blinding of patients
and personnel was considered unethical [e.g. repeated intramus-
cular (im) placebo administration] and therefore not performed.
However, the independent outcome assessors were blinded for
treatment allocation. Seven RCTs were registered in a public trial
register.34–40 The quality of the six observational papers was ac-
ceptable (Table S4). With regard to the pharmacological studies,
with focus on pharmacokinetics, overall, quality seems adequate
taking into account available methods of analysis at that time.
However, in some cases crucial information was missing, such as
gestational age (GA) or postnatal age (PNA), or the exact methods
used (Table S3). The complete assessment is included in Table S1.
Study population
As expected, the study population was quite heterogeneous,
including both term and preterm infants of different postnatal
ages. Four studies were performed in healthy newborns, admitted
for a non-infectious indication.17–20 The remaining 27 studies
included subjects with a clinical condition requiring antibiotics,
ranging from prophylactic use to culture-proven infection. Two
studies evaluated oral switch therapy in neonates with culture-
proven sepsis.31,41 Thirteen studies were performed in LMICs. In
these trials, antibiotic therapy indication was defined solely on clin-
ical symptoms.26,32,34–40,42,43,45,46
Absorption of oral antibiotics
Pharmacokinetic analysis and interpretation
In 10 papers serum levels were determined using the agar plate dif-
fusion method; the remaining and more recently published papers
used HPLC. Most studies provided descriptive data on absorption,
mainly Cmax without further pharmacokinetic estimates (e.g. V and
CL). Three papers provided AUC estimates.21,23,28 Regarding inter-
pretation, six papers reported MIC cut-off values28–33 with only one
study reporting a T.MIC.
32 Extracted pharmacokinetic data and
administered doses are described in Table 2.
Penicillin
Penicillin, a narrow-spectrum b-lactam antibiotic, was the first oral
antibiotic studied in neonates.17 A weight-equivalent dose was
administered orally or im to small groups of healthy subjects of dif-
ferent age (preterm and term newborns, infants or children). This
resulted in a lower Cmax following oral compared with im adminis-
tration in all age groups. Moreover, a higher AUC following oral
administration was reported in newborns compared with older
children.
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Ampicillin/amoxicillin
Absorption of oral ampicillin and amoxicillin, both broad-spectrum
b-lactam antibiotics, was evaluated in several studies in newborns
(GA 28–40 weeks; PNA 0–6 days).19–22 Following im injection Tmax
was 30 min, whereas this was on average 4 h for oral therapy.
Compared with adults, Cmax was higher and was reached later in
neonates, with even higher levels found in preterm newborns. A
small switch study evaluated the bioavailability of ampicillin and
amoxicillin, reporting lower plasma concentrations following oral
administration compared with equivalent im doses (AUC oral/im,
ampicillin 59%, range 22%–94%; amoxicillin 75%).23 A random-
ized study in neonates suspected of a bacterial infection compared
oral with iv amoxicillin. Initial serum levels were higher in the iv
group but comparable concentrations were reached 2 h after oral
administration.30 Most recently a population pharmacokinetic
study has been performed among 44 neonates receiving paren-
teral gentamicin combined with oral amoxicillin.32 Sampling 2–3
and 6–8 h after administration showed concentrations exceeding
the susceptibility breakpoint for amoxicillin against Streptococcus
pneumoniae (MIC 2.0 mg/L) strains at both timepoints, meaning
that T.MIC is.50% for a 12 h dosing interval.
Flucloxacillin/nafcillin
Levels of flucloxacillin and nafcillin, both narrow-spectrum b-
lactam antibiotics, have been reported following single-dose
administration and combined with other antibiotics to newborns
(28–42 weeks GA; 0–6 days PNA). Both drugs appear to be
absorbed faster than other penicillins, with a Tmax of 2 h for both
following oral administration.18,19,22 The corrected bioavailability
of oral flucloxacillin (corrected for a change in terminal half-life)
was reported to be 47.7%, which is almost equivalent to that in
adults.25
Chloramphenicol
Chloramphenicol, a broad-spectrum antibiotic, is not generally
used in neonatal care due to substantial side effects (e.g. grey
baby syndrome).48 Plasma levels following identical oral and iv
dose administration have been evaluated, showing a lower
steady-state concentration following oral treatment (oral
13.3 mg/L; iv 25.7 mg/L).24 Similar results were found in a multi-
centre study, with only half of term infants reaching therapeutic
levels (recommended range in study 10–25 mg/L) following oral
administration (25–50 mg/kg/day q12h or q24h depending on
PNA).26
Efficacy of oral antibiotics
Amoxicillin
Amoxicillin is the most studied oral antibiotic in neonates with a
probable or proven bacterial infection. Its efficacy depends on the
T.MIC. In preterm and term newborns (PNA 1–8 days) with a
Records identified through
database searching
(n = 4559)
Additional records identified
through other sources
(n = 5)
Records after duplicates removed
(n = 3242)
Records excluded
(n = 3140)
•        Age > 28 days (n = 29)
•        Review or report (n = 32)
•        Full text not available (n = 6)
•        Not focussing on oral
          antibiotics (n = 4)
Records screened
(n = 3242)
Studies included in
qualitative synthesis
(n = 31)
Full-text articles assessed
for eligibility
(n = 102)
Full-text articles excluded
with reasons (n = 71)
Figure 1. Study selection.
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probable bacterial infection, no relapse was reported after oral
treatment (80–150 mg/kg/day q12h). Moreover, no side effects
occurred and all measured serum concentrations were reported to
be above the MICs of targeted pathogens.27,30 In a clinical study
on Escherichia coli urinary tract infection (UTI), four neonates
showed no re-infections in the next 2 years following a 14 day oral
treatment of 120 mg/kg/day (in an era with low E. coli amoxicillin
resistance).22 In an RCT including 21 neonates with suspected in-
fection, 11 switched to oral amoxicillin (120 mg/kg q8h) after 48 h
of iv therapy (ampicillin/netilmicin). The control group switched to
amoxicillin iv. All patients included in the study had negative blood
cultures and tolerated oral feeding well without any vomiting.
Concentrations remained above the MIC for E. coli for all but three
patients (n"2 iv,n"1 oral).28 Dose optimization through increasing
the dosing frequency was suggested and subsequently evaluated
in a second study. Ten infants switched to oral amoxicillin
(100 mg/kg/day q6h). All plasma concentrations were above the
MIC for E. coliwithout substantial side effects or re-infections.29
An uncontrolled iv-to-oral switch trial was performed in 222
term neonates with probable or proven group B-streptococcal
(GBS) sepsis. Subjects switched to oral amoxicillin (300 mg/kg/day
q6h) after 48 h of iv amoxicillin (100 mg/kg per day). All infants had
to be asymptomatic and enterally fed at the moment of switch.
Because of high serum concentrations, the dose was reduced (to
200 mg/kg/day q6h) in the remaining 158 patients. Serum levels
were all above the MIC for GBS. Moreover, therapy was well toler-
ated without any side effects or reinfections and a reduction of
5 days in hospital admission was seen.31
Amoxicillin/clavulanic acid
A retrospective study evaluated the clinical course and treatment
of 172 newborns with a UTI. An increase in use of oral instead of iv
therapy was seen over the years. In total, 119 patients switched to
oral amoxicillin/clavulanic acid (dose not reported) as continuation
therapy. None of the orally treated newborns experienced a re-
lapse in the 6 months after treatment.47 In another study, oral
amoxicillin/clavulanic acid (80 mg/kg/day q12h) was administered
successfully to neonates at risk of infection without any re-
infections or treatment failure in the first month after treatment
completion.44
Cefalexin
A study from Pakistan described the outcome of oral management
in neonates with clinical omphalitis. Omphalitis was categorized
based on severity; cases without sepsis were treated with cefalexin
suspension (50 mg/kg/day q8h) with a success rate of 99.5%,
showing that outpatient treatment of clinically well neonates with
omphalitis using oral therapy is feasible.46
Cefpodoxime
Switching therapy from iv to oral was performed in 36 term neo-
nates with a probable or proven bacterial infection. After 72 h of iv
treatment (ampicillin/sulbactam!amikacin), patients who were
asymptomatic switched to oral cefpodoxime (10 mg/kg/day), a
third-generation cephalosporin. Seventy-two matched controls
continued on iv therapy. Outcomes were comparable for the two
groups, with identical inflammatory parameters in the first week
of treatment and no mortality after 1 month. Admission duration
was significantly lower and breastfeeding rate was significantly
higher among neonates with an oral switch.41
Flucloxacillin
In a small switch study, performed in 1987, neonates at risk of sep-
sis switched to oral flucloxacillin combined with oral amoxicillin
after severe bacterial infection had been ruled out. Plasma concen-
trations following oral administration were all above the MIC cut-
offs for Staphylococcus aureus.25
Linezolid
In a retrospective study, five preterm infants (GA 28+3.5 weeks),
treated for late-onset sepsis, who experienced renal failure,
switched from iv vancomycin (30 mg/kg/day) to oral linezolid
(30 mg/kg/day q8h). Cmax for all patients but one was above the
measured MIC for the causative pathogen.33
Larger efficacy studies including trials in LMIC settings
Since there is a need for good outpatient-based management in
LMICs, several large trials have taken place evaluating regimens
including oral antibiotics. In a controlled trial in .80 villages in
India, health workers in the intervention villages were trained in
providing neonatal care.42,43 When clinical sepsis was suspected
but admission refused, neonates received home-based treatment
including oral co-trimoxazole. Sepsis-related mortality decreased
from 16.6% to 6.9% compared with the period before introduction.
Subsequently, several large RCTs comparing home-based antibiot-
ic regimens have been published. The evaluated regimens are
described in Table 3.
Three regimens were compared in 434 Pakistani children 0–
59 days old (72% were 28 days old). Higher treatment failure
rates were seen among patients treated with oral co-trimoxazole
plus gentamicin compared with other regimens.40 In a Nepalese
study, oral co-trimoxazole was administered in combination with
im gentamicin to 67 newborns with a possible bacterial infection.45
The authors reported a 100% completion rate of oral therapy with-
out any treatment failure. An Ethiopian trial evaluated the imple-
mentation of im gentamicin and oral amoxicillin.36 When infection
was suspected, pre-referral medication was given and the patient
was referred to the hospital. If referral was not possible, the inter-
vention group continued with home-based treatment; the control
group did not receive further treatment. Results seem promising,
with a decline in mortality from 17.9 deaths per 1000 live births at
baseline to 9.4 per 1000 in the intervention group. In the compari-
son group, mortality rates declined to a lesser extent, from 14.4 to
11.2 per 1000. However, mortality rates were not significantly
lower in the intervention group compared with the control
(P"0.33).
Three RCTs, with a total of 8834 subjects, compared regimens
including oral amoxicillin with standard im regimens (penicillin/
gentamicin) in newborns at risk of severe infection. The first trial, in
Bangladesh, compared three regimens, including an oral switch
regimen, among 2490 children (10% aged 0–6 days)37 The second
trial, in the Democratic Republic of the Congo, Kenya and Nigeria
(AFRINEST study) included 3564 infants 0–59 days old (30% 0–
6 days old)39 comparing four regimens including one oral switch to
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amoxicillin. The third study included 2453 infants (44% 0–6 days
of age) evaluating similar regimens.35 Heterogeneity between
studies was low. Primary outcome was treatment failure within
8 days, defined as death, clinical deterioration, hospital admission
or treatment-related serious adverse events. The combined OR for
the orally treated group was 0.95 (95% CI 0.79–1.16; I2 0%)
Mortality within 2 weeks after enrolment was comparable in both
groups, with an OR of 1.11 (95% CI 0.72–1.72; I2 0%). Forest plots
are shown in Figure 2.
Finally, two trials evaluated the use of oral amoxicillin in neo-
nates with tachypnoea as a single symptom of possible infection.
The first, in which oral treatment was compared with placebo in
849 infants (78% 0–28 days old; dropout:n"121), showed a higher
mortality in the placebo group compared with the treatment
group, underlining the potential benefits of antibiotic treatment in
infants with fast breathing alone.34 A second trial, including 2333
neonates (38% 0–6 days old), showed equivalence of oral amoxi-
cillin compared with an im regimen in newborns with fast breath-
ing, with comparable treatment failure rates [22% (im regimen)
versus 19% (oral regimen)] and mortality rates (,1% in both
groups).38
Discussion
In this systematic review, we collected the currently available evi-
dence on oral antibiotics in neonates. While oral administration is
not commonly considered at present in neonates, several pharma-
cological and efficacy studies have been performed with different
types of antibiotics.
In general, adequate serum levels according to the MICs of rele-
vant pathogens can be achieved after oral administration in neo-
nates. Inter-individual variation is observed, which has also been
reported following iv administration and should therefore not be
used as an argument for discarding oral therapy. Cmax is reached
later after oral administration compared with other routes. Thus,
as in older patients, initial therapy should consist of iv antibiotics to
quickly reach target concentrations, but can subsequently be
switched to oral therapy once the neonate is clinically well.
The efficacy studies showed equal relapse rates and good toler-
ation of oral therapy compared with iv therapy without reporting
an increase in side effects. Moreover, in two studies oral adminis-
tration led to a shorter stay in hospital and more exclusively
breast-fed infants. In LMICs, mortality rates have decreased
through the introduction of home-based therapy when referral is
not possible and simplified antibiotic regimens with an oral switch
have shown efficacy similar to that of standard im therapy.
The strength of this review is the fact that we provide a com-
plete overview of all retrieved studies on oral antibiotic use in neo-
nates. Although this provides a great historical overview of an idea
that has existed since the 1950s, the heterogeneity of the studies
found makes pooling and generalizability to current clinical prac-
tice difficult. In an attempt to translate findings to contemporary
practice, limitations will be discussed in the light of study design
and setting, ethics, techniques used and analysis.
First, study groups were small and without randomization, ex-
cept for a few large RCTs, introducing a possible selection bias with
exclusion of the sicker newborns. In most studies, clinical efficacy,
bacterial re-infection or treatment failure is used as the primary
outcome. Given the fact that the bacterial re-infection rate is low, a
much larger study sample is needed to show non-inferiority or effi-
cacy of oral treatment.49 Moreover, the clinical indication for anti-
biotic treatment and infection severity is unclear in a number of
studies; therefore data cannot be translated to current practice.
The included studies were performed in both preterm and term
infants, sometimes without providing the GA or PNA of the sub-
jects. Drug clearance differs between preterm and term infants
and improves with increasing postnatal age, thereby influencing
plasma concentrations.50 Finally it must be stressed that a great
Table 3. LMIC trials and antibiotic regimens
Author Intervention Control
Bang et al.42,43 gentamicin im! co-trimoxazole syrup no treatment
Zaidi40 (i) ceftriaxone (50 mg/kg/day) im (7 days) benzylpenicillin im! gentamicin im (7 days)
(ii) oral co-trimoxazole (5 mg/kg q8h)! gentamicin im (7 days)
Baqui et al.*37 (i) oral amoxicillin (50 mg/kg q12h)! gentamicin im (7 days) benzylpenicillin im! gentamicin im (7 days)*
(ii) benzylpenicillin! gentamicin im (2 days) followed by oral
amoxicillin (5 days)*
Tshefu et al.*39 (i) oral amoxicillin (50 mg/kg q12h)! gentamicin im (7 days) benzylpenicillin im! gentamicin im (7 days)*
(ii) benzylpenicillin! gentamicin im (2 days) followed by oral
amoxicillin (5 days)
(iii) gentamicin im! oral amoxicillin (2 days) followed by oral
amoxicillin (50 mg/kg q12h) (5 days)*
Tshefu et al.38 oral amoxicillin (50 mg/kg q12h) benzylpenicillin im! gentamicin im (7 days)
Mir et al.*35 (i) gentamicin im! oral amoxicillin (50 mg/kg q12h) (7 days) benzylpenicillin im! gentamicin im (7 days)*
(ii) procaine benzylpenicillin im! gentamicin (2 days) followed by
oral amoxicillin (5 days)*
Degefie Hailegebriel et al.36 oral amoxicillin (40 mg/kg q8h)! gentamicin im (7 days) no treatment
Tikmani et al.34 oral amoxicillin (50 mg/kg q12h) (7 days) placebo
*Included in the meta-analysis.
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variety of antibiotic regimens have been used, including single-dose
administration, and sometimes without mentioning the adminis-
tered dose. Some of the therapies and regimens are rarely prescribed
nowadays, partly due to increased concerns regarding antibiotic re-
sistance and the availability of alternatives with fewer side effects.
In LMICs, simplified regimens including oral antibiotics are al-
ready recommended by the WHO when referral is not possible.51
Unfortunately, the setting differs greatly from HICs, with refusal of
hospital admission still being common and accepted, especially in
remote areas. In addition to the differences in setting, the majority
of patients are solely diagnosed on clinical symptoms since diag-
nostic tools are often lacking, possibly leading to an overestimation
of the actual number of bacterial infections. Furthermore, the in-
tensity of surveillance due to the execution of the study combined
with exclusion of the sicker neonates may have biased mortality
rate numbers.
Regarding the pharmacokinetic analysis, ethics requirements of
studies have changed and the same holds true for the administra-
tion of antibiotics to healthy newborns. With regard to blood sam-
pling, it is no longer considered ethical to collect large volumes or
many samples in neonates. Advanced population pharmacoki-
netic approaches should be applied in further research, using a
reduced number of samples per newborn.52
Further, improved knowledge and better techniques have led to
novel antibiotic assays, replacing agar plate dilution methods.
Advanced analysis programs are available in order to develop
pharmacokinetic models, used for prediction of exposure and drug
response, following different dosage regimens in a target popula-
tion. Those models take into account covariates such as gestation-
al and postnatal age or disease characteristics that possibly
influence the pharmacokinetics and dynamics of a drug. Notably,
none of the included papers reported covariates in their analysis.
Finally, for the interpretation of results and thus the evaluation
of efficacy, the pharmacological mode of action of the specific
antibiotic should be considered. The effect of b-lactam antibiotics
depends on T.MIC, whereas for aminoglycosides it depends on the
Cmax/MIC ratio. Although six papers do refer to MIC, only one
reports T.MIC. Comparison of Cmax with a single MIC value in case
of b-lactam antibiotics has no clinical relevance and cannot be
used as a relevant surrogate marker for therapy efficacy.
Moreover, MIC levels have increased in recent years, due to an in-
crease in bacterial resistance. In 1992, Giustardi and Coppola30
reported an amoxicillin MIC of 5 mg/L for E. coli, whereas now an
MIC of .8 mg/L is advised to properly treat an E. coli infection.
Given these limitations, the currently published studies cannot be
used as conclusive evidence to safely change our current guide-
lines on management of neonatal bacterial infection. However,
our findings do give the impression that such studies may be
undertaken safely.
Conclusion and future directions
Early switch to oral antibiotics after a short course of iv antibiot-
ics could be promising in term neonates with a (probable) bac-
terial infection. This claim is partly supported by the available
evidence retrieved in this systematic review. Unfortunately, the
lack of large well-designed studies in a high-income setting,
evaluating the efficacy of oral antibiotics, together with the
uncertainties regarding pharmacokinetics has obstructed fur-
ther implementation. Future research should focus on the clinic-
al efficacy of oral therapy and the safety of iv-to-oral antibiotic
switch therapy in neonates using different types of antibiotics,
taking into account the mode of action of the specific antibiotic.
These studies should include pharmacokinetic analyses when
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Figure 2. (a) Forest plot comparing treatment failure of reference treatment (penicillin/gentamicin im for 7 days) with switch regimen (penicillin/gen-
tamicin im for 2 days followed by oral amoxicillin for 5 days). The regimens used are further described in Table 3. (b) Forest plot comparing mortality
of reference treatment (penicillin/gentamicin im for 7 days) with switch regimen (penicillin/gentamicin im for 2 days followed by oral amoxicillin for
5 days). The regimens used are further described in Table 3. PEN, penicillin; GEN, gentamicin.
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possible, to properly evaluate currently used dosing regimens.
Once iv-to-oral switch therapy is proven to be safe and effective
in neonates, its implementation may have a strong effect on
health-cost reduction and quality of life.
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